{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:10:11Z","timestamp":1791267011083,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.245","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T06:40:46Z","timestamp":1501483246000},"page":"2388-2397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-4204","authenticated-orcid":false,"given":"E","family":"Hadzijusufovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Albrecht-Schgoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-5300","authenticated-orcid":false,"given":"K","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-2281","authenticated-orcid":false,"given":"F","family":"Grebien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Schgoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Herndlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Theurl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W R","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-2770","authenticated-orcid":false,"given":"U","family":"Rix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Sadovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G H","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wojta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-1768","authenticated-orcid":false,"given":"G","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kirchmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"BFleu2017245_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu2017245_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattler","year":"2003","unstructured":"Sattler M, Griffin JD . Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4\u201310.","journal-title":"Semin Hematol"},{"key":"BFleu2017245_CR4","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.1038\/sj.onc.1206081","volume":"21","author":"BJ Druker","year":"2002","unstructured":"Druker BJ . Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541\u20138546.","journal-title":"Oncogene"},{"key":"BFleu2017245_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu2017245_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/10245330500234195","volume":"10","author":"M Copland","year":"2005","unstructured":"Copland M, Jorgensen HG, Holyoake TL . Evolving molecular therapy for chronic myeloid leukaemia\u2013are we on target? Hematology 2005; 10: 349\u2013359.","journal-title":"Hematology"},{"key":"BFleu2017245_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","volume":"35","author":"MW Deininger","year":"2007","unstructured":"Deininger MW . Optimizing therapy of chronic myeloid leukemia. Exp Hematol 2007; 35: 144\u2013154.","journal-title":"Exp Hematol"},{"key":"BFleu2017245_CR10","first-page":"534","volume":"90","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M . New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90: 534\u2013541.","journal-title":"Haematologica"},{"key":"BFleu2017245_CR11","first-page":"S22","volume":"6","author":"J Cortes","year":"2008","unstructured":"Cortes J, Kantarjian H . Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw 2008; 6: S22\u2013S30.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFleu2017245_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","volume":"7","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Deininger MW, Druker BJ . AMN107: tightening the grip of imatinib. Cancer Cell 2005; 7: 117\u2013119.","journal-title":"Cancer Cell"},{"key":"BFleu2017245_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/10428190801896210","volume":"49","author":"G Saglio","year":"2008","unstructured":"Saglio G, Ulisciani S, Bosa M, Cilloni D, Rege-Cambrin G . New therapeutic approaches and prognostic factors in chronic myeloid leukemia. Leuk Lymphoma 2008; 49: 625\u2013628.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017245_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2017245_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542\u20132551.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/10428191003637282","volume":"51","author":"G Rosti","year":"2010","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M . Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk Lymphoma 2010; 51: 583\u2013591.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017245_CR17","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933\u20134938.","journal-title":"Blood"},{"key":"BFleu2017245_CR18","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/14796694.4.5.611","volume":"4","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Cortes J . Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol 2008; 4: 611\u2013621.","journal-title":"Future Oncol"},{"key":"BFleu2017245_CR20","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055\u20134063.","journal-title":"Blood"},{"key":"BFleu2017245_CR21","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","volume":"106","author":"EH Stover","year":"2005","unstructured":"Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106: 3206\u20133213.","journal-title":"Blood"},{"key":"BFleu2017245_CR22","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","volume":"98","author":"Z Racil","year":"2013","unstructured":"Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013; 98: e124\u2013e126.","journal-title":"Haematologica"},{"key":"BFleu2017245_CR23","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","volume":"99","author":"D Rea","year":"2014","unstructured":"Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014; 99: 1197\u20131203.","journal-title":"Haematologica"},{"key":"BFleu2017245_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533\u2013539.","journal-title":"Am J Hematol"},{"key":"BFleu2017245_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310\u20131315.","journal-title":"Leukemia"},{"key":"BFleu2017245_CR26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316\u20131321.","journal-title":"Leukemia"},{"key":"BFleu2017245_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347\u20131348.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2017245_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ejh.12096","volume":"90","author":"L Levato","year":"2013","unstructured":"Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S . Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013; 90: 531\u2013532.","journal-title":"Eur J Haematol"},{"key":"BFleu2017245_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quintas-Cardama","year":"2012","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J . Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12: 337\u2013340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu2017245_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ajh.22051","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86: 610\u2013611.","journal-title":"Am J Hematol"},{"key":"BFleu2017245_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","volume":"145","author":"N Alhawiti","year":"2016","unstructured":"Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 2016; 145: 54\u201364.","journal-title":"Thromb Res"},{"key":"BFleu2017245_CR32","doi-asserted-by":"crossref","unstructured":"El-Agamy DS . Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. Hum Exp Toxicol 2016; pii:0960327116681649.","DOI":"10.1177\/0960327116681649"},{"key":"BFleu2017245_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1076029614550817","volume":"21","author":"A Katgi","year":"2015","unstructured":"Katgi A, Sevindik OG, Gokbulut AA, Ozsan GH, Yuksel F, Solmaz SM et al. Nilotinib does not alter the secretory functions of carotid artery endothelial cells in a prothrombotic or antithrombotic fashion. Clin Appl Thromb Hemost 2015; 21: 678\u2013683.","journal-title":"Clin Appl Thromb Hemost"},{"key":"BFleu2017245_CR34","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V122.21.3907.3907","volume":"122","author":"A Mian","year":"2013","unstructured":"Mian A, Rafiei A, Metodieva A, Haberbosch I, Zeifman A, Titov I et al. PF-114, a novel selective Pan BCR\/ABL inhibitor targets the T315I and suppress models of advanced Ph+ ALL. Blood 2013; 122: 3907.","journal-title":"Blood"},{"key":"BFleu2017245_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0021-9150(03)00097-2","volume":"170","author":"S Blankenberg","year":"2003","unstructured":"Blankenberg S, Barbaux S, Tiret L . Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191\u2013203.","journal-title":"Atherosclerosis"},{"key":"BFleu2017245_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1042\/cs1030123","volume":"103","author":"J Hulthe","year":"2002","unstructured":"Hulthe J, Wikstrand J, Mattsson-Hulten L, Fagerberg B . Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men: the atherosclerosis and insulin resistance (AIR) study. Clin Sci (Lond) 2002; 103: 123\u2013129.","journal-title":"Clin Sci (Lond)"},{"key":"BFleu2017245_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0046-8177(99)90274-5","volume":"30","author":"HC Bankl","year":"1999","unstructured":"Bankl HC, Grossschmidt K, Pikula B, Bankl H, Lechner K, Valent P . Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol 1999; 30: 188\u2013194.","journal-title":"Hum Pathol"},{"key":"BFleu2017245_CR38","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4049\/jimmunol.162.2.1032","volume":"162","author":"C Sillaber","year":"1999","unstructured":"Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999; 162: 1032\u20131041.","journal-title":"J Immunol"},{"key":"BFleu2017245_CR39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329\u20131340.","journal-title":"Lancet"},{"key":"BFleu2017245_CR40","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2017245_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P . Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 2015; 125: 901\u2013906.","journal-title":"Blood"},{"key":"BFleu2017245_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1681\/ASN.2004050392","volume":"16","author":"M Lassila","year":"2005","unstructured":"Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 363\u2013373.","journal-title":"J Am Soc Nephrol"},{"key":"BFleu2017245_CR43","doi-asserted-by":"publisher","first-page":"e85231","DOI":"10.1371\/journal.pone.0085231","volume":"8","author":"EM Chislock","year":"2013","unstructured":"Chislock EM, Pendergast AM . Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One 2013; 8: e85231.","journal-title":"PLoS One"},{"key":"BFleu2017245_CR44","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783\u20131796.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017245","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:25:18Z","timestamp":1692905118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu2017245"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.245","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]},"assertion":[{"value":"22 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EH received honoraria from Novartis. GHS received honoraria from Amgen, Astra Zeneca, Boehringer Ingelheim, BMS, Elli Lilly, Merck, Novo-Nordisk, Novartis, Pfizer and Sanofi-Aventis. DW received honoraria from Pfizer, BMS, Novartis, and Ariad and Research Grants from Pfizer and Ariad. RK received honoraria from Ariad and a Research Grant from Ariad. GH received honoraria form Novartis and Ariad. PV received honoraria from Novartis, Celgene, Pfizer, Deciphera, BMS, Ariad, and Incyte; and research grants from Novartis, Deciphera and Ariad. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}